Intra abdominal infections are a group of diseases of abdomen and are one of the most common causes of mortalities across the globe. These include peritonitis, intra abdominal abscess, diverticulitis, appendicitis, food poisoning and pelvic inflammatory disease. Post surgical infections are a major cause of intra abdominal infections. The infections can also occur due to inflammatory bowel disease, ruptured appendix, and intestinal infection. Symptoms may vary depending on the anatomical location of infection. Common symptoms include abdominal pain, chills, diarrhea, nausea, lack of appetite, fever, rectal tenderness and vomiting. Initial leakage of the gastrointestinal microflora into the peritoneal cavity results in peritonitis and secondary septicemia, and is usually followed by localized abscess. Severe sepsis is one of the prominent factors increasing mortality rates in intra abdominal infections.
Intra abdominal infections are most frequently polymicrobial. Major causative agents of intra abdominal infections include E. coli, Streptococci, Enterococci, Klebsiella, Pseudomonas, and H. pylori. The diseases are diagnosed by blood tests, abdominal X-ray, computed tomography (CT) and ultrasound. Due to large number of causative agents involved, poor prognosis and varied symptoms, the disease is difficult to diagnose and treat. Factors influencing the prognosis of complicated intra-abdominal infections include age, immunosuppression, pre-existing diseases, extended peritonitis, occurrence of septic shock, organ failures, and delay in therapy. Broad spectrum antibiotics are the main choice of treatment, but they may also alter the normal gastrointestinal microflora. Following is the list of antibiotics mainly prescribed for intra abdominal infections:
Vancomycin is strictly recommended for treatment of proven intra abdominal infection due to Methicillin-resistant Staphylococcus aureus (MRSA) due its serious side effects. Intra abdominal infections can be easily cured if diagnosed and treated in the early stage of infection. There have been cases where drug resistant microbial species have set infections to critical levels. Under such circumstances, surgical methods can be used.
These methods for treatment of intra abdominal infections include intraoperative peritoneal irrigation with saline, antibiotic solutions, and povidone-iodine. This method is widely used to manage patients with secondary bacterial peritonitis. Complicated intra abdominal infections are an important cause of morbidity and are frequently associated with poor prognosis, making treatment difficult.
Pharmaceutical companies are also trying to discover new drugs for the treatment of intra abdominal infections. Pfizer, Merck Sharp & Dohme Corp. and Tetraphase Pharmaceuticals, Inc. are some of the major companies conducting clinical trials for treatment for intra abdominal infections. As newer drugs receive regulatory approvals, market will expand its scope and grow rapidly. As the market is matured, it has well penetrated in developing as well as under developed countries. Majority of the drugs prescribed for treating intra abdominal infections include generic antibiotics. Due to this a large number of small players operate in the market. India being the home for generic drugs manufacturers, low cost drugs are made available to lower income group; thus increasing market penetration.
Some of the key players in the intra abdominal infection market include AstraZeneca PLC, Merck & Co., Inc., Atox Bio Inc., Pfizer, Inc. Major generic drug manufacturers include Aurobindo Pharma Ltd., Dr Reddys Labs Ltd, and Teva.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.